



# Oncology Medical Home

The below is the list of quality and value measures that have been approved by the OMH Steering Committee.

<b>Patient Care Measures</b>
% of cancer patients that received a treatment plan prior to the administration of chemotherapy.
% of cancer patients with documented clinical or pathologic staging prior to initiation of first course of treatment.
% of chemotherapy treatments that have adhered to NCCN guidelines or pathways.
Antiemetic drugs given appropriately with highly emetogenic chemotherapy treatments.
% of cancer patients undergoing treatment with a chemotherapy regimen with a 20% or more risk of developing neutropenia and also received GCSF/white cell growth factor.
<i>NEW 08/07/13</i> - Appropriate use of advanced imaging for early stage breast cancer patients.
<i>NEW 08/07/13</i> - Appropriate use of advanced imaging for early stage prostate cancer patients.
<i>NEW 08/07/13</i> - Presence of patient performance status prior to treatment.
<b>Resource Utilization</b>
# of emergency room visits per chemotherapy patient per year.
# of hospital admissions per chemotherapy patient per year.
<b>Survivorship</b>
% of cancer patients that received a survivorship plan within X days after the completion of chemotherapy.
% of chemotherapy patients that received psycho/social screening and received measurable interventions as a result of the psycho/social screening.

Updated 08/07/13

<b>Survivorship</b>
Survival rates of stage I through IV breast cancer patients.
Survival rates of stage I through IV colorectal cancer patients.
Survival rates of stage I through IV NSC lung cancer patients.
<b>End of Life</b>
% of patients that have Stage IV disease that have end-of-life care discussions documented.
Average # of days under hospice care (home or inpatient) at time of death.
% of patient deaths where the patient died in an acute care setting.
A measurement of chemotherapy given near end of life.
<b>Other</b>
Patient satisfaction reporting and scoring.

